NAD Supplementation and Vascular Health in PAD

University of Oklahoma (OU)

Status and phase

Active, not recruiting

Phase 2

Phase 1

Conditions

Peripheral Artery Disease

Treatments

Drug: Nicotinamide riboside

Study type

Interventional

Funder types

Other

Identifiers

NCT06534944

15457

Details and patient eligibility

About

This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.

Full description

Peripheral artery disease (PAD) is a prevalent age-related vascular pathology and the third leading cause of cardiovascular morbidity and mortality among older adults. Accumulating evidence indicates that PAD is associated with generalized endothelial dysfunction that expands from the periphery to central circulation and from macro- to microcirculation. One of the mechanisms that contributes to vascular dysfunction in aging and age-related diseases is the decline in the Nicotinamide Adenine Dinucleotide (NAD) levels. Importantly, recent reports indicate that age-associated decreases in NAD are exacerbated in age-related diseases, including in patients with PAD. Clinical data demonstrate that NAD levels can be increased via per os supplementation with the NAD precursor nicotinamide riboside (NR). Although few ongoing studies provide initial evidence that NAD supplementation with NR may benefit vascular health in older adults, including potential improvements in blood pressure and aortic stiffness, the effects of NR supplementation on vascular health in PAD is understudied. This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.

Enrollment

8 patients

Sex

All

Ages

55 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

diagnosis of PAD
intermittent claudication
limited walking capacity

Exclusion criteria

macologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension
major depressive disorder
current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment)
neurodegenerative diseases